Monday, December 16, 2019 9:37:13 AM
“Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
BY GlobeNewswire
— 8:00 AM ET 12/16/2019
30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile
Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January
FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Loading...
Loading...
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced summary data from 20 patients receiving a single dose of CLR 131 in its Phase 2 CLOVER-1 trial in select relapsed/refractory (RR) B-cell malignancies. The company had previously announced data from 10 multiple myeloma patients receiving a single dose of CLR 131 in February 2019, which showed a 30% overall response rate (ORR).
The Phase 2 CLOVER-1 study is designed to identify a safe and efficacious dose and regimen to be used in a pivotal study for select hematologic indications. The 20 evaluated patients, included 10 subjects with relapsed/refractory multiple myeloma, and 10 with relapsed/refractory B-cell lymphoma. The median age was 71 (range 52-82), including 7 females and 13 males, with a median of 6 prior systemic therapies for multiple myeloma and 4 for patients with lymphoma. Eight patients had prior autologous stem cell transplant therapy. Data from these 20 patients showed a 30% ORR, a 75% clinical benefit rate, an average progression free survival of 4.5 months and an acceptable and expected safety profile.
“The 30% ORR seen suggests that CLR 131 treatment at the single 25 mCi/m2 bolus dose may have activity in these heavily pre-treated patients,” said James Caruso, president and CEO of Cellectar Biosciences ( CLRB
Loading...
Loading...
). “We recently presented data at ASH on 19 patients with relapsed, refractory multiple myeloma, which showed improved efficacy and safety with fractionated doses vs. the single bolus dose, and patients receiving a fractionated dose of 37.5mCi showed a 50% ORR. As background, recently approved drugs for this indication have demonstrated approximate ORRs of 25% in a similar patient population and up to 29% as a third line treatment. We plan to provide additional data in patients who are receiving higher fractionated doses of CLR 131 in January.”
The primary adverse events (AEs) seen were cytopenias, including thrombocytopenia, anemia, neutropenia, and decreased white blood cell count. The hematologic AEs were expected, manageable and followed a predictable timeline to nadir (average 49 days) and subsequent recovery (average 16 days post nadir). Patients with disease in the bone marrow experienced more cytopenias than did patients with no detectable disease in the bone marrow. All patients recovered from the cytopenias.”
Recent CLRB News
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:03:04 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 01:00:28 PM
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study • GlobeNewswire Inc. • 01/30/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:30:40 PM
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million • GlobeNewswire Inc. • 01/25/2024 11:40:00 AM
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient • GlobeNewswire Inc. • 01/22/2024 11:40:00 AM
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data • GlobeNewswire Inc. • 01/16/2024 11:40:00 AM
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results • GlobeNewswire Inc. • 01/12/2024 11:44:16 AM
- Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting • GlobeNewswire Inc. • 01/11/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 11:02:18 AM
- Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
- Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:09:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:07:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:05:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:04:10 AM
- Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform • GlobeNewswire Inc. • 12/12/2023 01:30:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM